U081 Malignancy Risk and Immunomodulatory Therapy
DESCRIPTION
Cancer risk and inflammatory disease are intrinsically linked, and many patients with active malignancy also have dermatologic conditions requiring systemic therapy. Consideration of each patient’s unique situation is needed in order to recommend safe and effective therapies that modulate their inflammatory disease while not leading to immunosuppression or risking further carcinogenesis. This session will serve to educate all dermatology clinicians regarding the links between the immune system and cancer development, risks of oral and biologic immunomodulatory therapy on both the development and progression of cancer, and how to select safe and effective therapies for patients with a known non-skin malignancy.
LEARNING OBJECTIVES
Summarize the processes of solid organ or hematologic carcinogenesis, and how the immune system is involved in malignancy surveillance and monitoring, including cytokines relevant to targeted dermatologic therapies.
Recognize what is known regarding malignancy risks of traditional oral small molecule, such as methotrexate, cyclosporine, mycophenolate, as well as advanced therapies including oral JAK and TYK2 inhibitors, and dermatology-relevant classes of targeted biologic therapies.
Select safe treatment approaches for patients needing systemic immunomodulatory therapies in the context of having an active or prior malignancy.
DIRECTOR
Drew Kuraitis, MD, PhD, FAAD
Roswell Park Comprehensive Cancer Center
SPEAKERS
Katherine Brag, MD, FAAD
Tom Hillary, MD
DISCLOSURES
Katherine Brag, MD, FAAD
No financial relationships exist with ineligible companies.
Tom Hillary, MD
No financial relationships exist with ineligible companies.
Drew Kuraitis, MD, PhD, FAAD
Ortho Dermatologics – Consultant (1099 relationship)(Fees); Pfizer Inc. – Advisory Board(Honoraria); Sun Pharmaceutical Industries Ltd. – Consultant (1099 relationship)(Honoraria); UCB – Advisory Board(Honoraria); Veradermics – Advisory Board(Honoraria);